secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2026-08-10T20:12:21+00:00
Accession:  0001193125-26-342402
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q2 2026: cash $243.2M, net loss $40.4M; NKX019 trials advance
--------------------------------------------------------------------

- Cash, equivalents, restricted cash and investments $243.2M as of June 30, 2026; expected to fund operations into 2029.
- Q2 2026 net loss $40.4M ($0.54 per share); R&D expense $29.0M, G&A expense $14.1M.
- Enrollment continues across Ntrust-1 and Ntrust-2 at 4B cells/dose (12B total) in all autoimmune indications.
- Outpatient dosing underway at community sites after FDA agreement; initial Ntrust data expected at 2026 medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/0001193125-26-342402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/nktx-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer